08 Sep 2022 Governance
Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II
On behalf of the Leukaemia UK team, Chair of Trustees, Chris Corbin OBE, has made the following statement:
“We are extremely saddened to hear the news of the death of Her Majesty Queen Elizabeth II. 
Together with the nation and people around the world, we remember a true leader who gave her life to duty. The Queen’s dedication, diligence and integrity were an inspiration to all and we are thankful for an inspiring monarch, who gave her life in service of her country and the Commonwealth.
The Queen’s support for the charity sector has enabled charities in the UK to thrive during her reign and will have a lasting impact for those whom the charities support.
We share our condolences with the entire Royal Family and especially the Queen’s children and grandchildren. Our thoughts are with them at this very difficult time.”
Related posts
18 September 2025
1 in 4 leukaemia patients in England experiences an avoidable delay in diagnosis
A first of its kind study, commissioned by Leukaemia UK, has revealed that a quarter (26%) of leukaemia patients in England experience avoidable delays in their diagnosis, resulting in a…
18 October 2021
Leukaemia UK drives forward progress for leukaemia research through five new John Goldman Fellowships for 2021
Leukaemia UK announces five new John Goldman Fellows for 2021 to accelerate progress and stop the disease devastating lives.
20 October 2023
Emerging leaders accolade for former Leukaemia UK John Goldman Fellows
Former Leukaemia UK John Goldman Fellows, Dr Matthew Blunt, University of Southampton and Dr Konstantinos Tzelepis, University of Cambridge have been recognised as ‘Emerging Leaders in Leukaemia’ by the major…
25 November 2025
Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl
Today, NICE announced its recommendation for Aucatzyl (obecabtagene autoleucel), a CAR-T therapy, to be made available on the NHS for treating adults aged 26 and over with relapsed or refractory…